Treace Medical Q3 2026: Cost Cuts Drive First Positive EBITDA

Treace Medical Concepts posted a Q3 2026 GAAP loss of $0.19 per share, beating expectations, while revenue of $48.25 million also came in ahead of the analyst target. The beat came even as total revenue fell 3.9% year over year, which management attributed to a deliberate mix shift toward lower-priced minimally invasive products.

Total operating expenses dropped 10% to $49.88 million, led by lower sales and marketing spend. That discipline flipped Adjusted EBITDA to a positive $309,000, compared with a loss of $2.59 million in the same quarter a year earlier, a milestone for a company that has been working toward profitability.

GAAP net loss narrowed 23% to $12.57 million, though the figure includes $2.71 million in intellectual property litigation costs. On the volume side, underlying case growth was described as accelerating at a double-digit rate, and roughly 45% of Lapiplasty surgeon users had adopted one or more of the three new bunion systems launched in Q3 2025, up from 40% the prior quarter.

Management tightened its full-year 2026 revenue guidance to a range of $206 million to $210 million. More notably, the expected Adjusted EBITDA loss for the full year was revised to $1.0 million to $2.0 million from a prior range of $3.0 million to $5.0 million, effectively halving the anticipated shortfall and putting a breakeven outcome within striking distance for a company carrying a market cap of $272 million.

The revenue mix shift is worth watching closely in coming quarters. Bunion kit sales to stocking distributors weighed on reported revenue, but excluding those sales, bunion kit volume grew and revenue rose at a mid-single-digit rate year over year. If that underlying trend continues and the company sustains its expense discipline, the trajectory toward full profitability becomes more credible than the headline revenue decline would suggest.